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Two mutant alleles of RAS2 were discovered that dominantly interfere with wild-type RAS function in the
yeast Saccharomyces cerevisiae. An amino acid substitution which caused the dominant interference was an
alanine for glycine at position 22 or a proline for alanine at position 25. Analogous mutations in human H-ras
also dominantly inhibited RAS function when expressed in yeast cells. The inhibitory effects of the mutant RAS2
or H-ras genes could be overcome by overexpression of CDC25, but only in the presence of wild-type RAS.
These results suggest that these mutant RAS genes interfere with the normal interaction of RAS and CDC25
proteins and suggest that this interaction is direct and has evolutionarily conserved features.
RAS proteins share a feature common to other guanine-
nucleotide-binding proteins in that the GTP-bound form of
the protein, but not the GDP-bound form, activates the
target effector (1, 20). Biochemical evidence in support of
this comes from studies in Saccharomyces cerevisiae in
which RAS2 protein has been shown to activate adenylate
cyclase when bound to GTP, but not when bound to GDP
(11, 15, 16), and from studies of frog oocytes, in which only
the GTP-bound form of RAS protein induces oocyte matu-
ration (44). It is therefore of interest to identify components
that can control the guanine-nucleotide bound to RAS pro-
teins and thereby control its activity. Recently, a protein has
been identified which accelerates hydrolysis of GTP by
mammalian RAS proteins (19, 44). In other guanine-nucle-
otide-binding protein systems, the conversion of GDP-bound
to GTP-bound protein is controlled by the activity of distinct
nucleotide exchange catalysts (20, 41). There is some pre-
liminary evidence that, in S. cerevisiae, the CDC25 protein
may fulfill this role for RAS1 and RAS2 proteins (6, 10, 38).
The CDC25 gene was originally identified by a tempera-
ture-sensitive (Ts) mutation that causes S. cerevisiae to
arrest their progression through the cell cycle uniformly in
Gl (37). This terminal arrest phenotype is exhibited by other
cell cycle mutations such as cdc35, which is allelic to CYR],
the gene that encodes adenylate cyclase (3, 8, 24, 33).
CDC25 mutations significantly reduce cyclic AMP levels (6,
7, 32). Epistasis studies have suggested that the CDC25 gene
product acts upstream of RAS proteins in the control of
adenylate cyclase (6, 31, 38). Based on the GTP requirement
for adenylate cyclase activity in membranes prepared from
cdc25 mutants, yeast RAS proteins appear to require CDC25
function to become bound to GTP (6).
In this report, we have utilized dominant-interfering mu-
tants of RAS2 and H-ras to further explore the relationship
between CDC25 and RAS proteins.
MATERIALS AND METHODS
Strains. Wild-type strains SP1 (MATa leu2 ura3 his3 trpl
ade8 gal2 canl) and RS16-4C (MATTa ura3 his3 trpl ade2
* Corresponding author.
t Present address: Department of Biochemistry, Robert Wood
Johnson Medical School, Piscataway, NJ 08854.
ade8) were used in these studies (36). The rasl:: URA3
RAS2ValIl9 strain PT1-6 was derived from SP1 by transfor-
mation (36). PT1-6 is the parental strain for the STS rever-
tant series, including STS13, STS35, and STS37. The ras2::
URA3 strain KP-2 was derived from SP1 by transformation
(26). RS60-3A (MATa RAS2Vall9, Ala-22 ura3 his3 ade8 trpl)
was derived from a cross between STS13 and RS16-4C.
SDR-3 is a His' transformant of SP1 containing plasmid
pGALJO-H-raSVal-12, Ala-15 integrated at the HIS3 locus (see
below).
Cloning and assaying the activity of the dominant RAS2(Ts)
alleles. Genomic DNA from strains STS13, STS35, and
STS37 was digested to completion with EcoRI and HindIII,
and DNA libraries were constructed in pUC9 from size-
selected DNA. The RAS2 locus is contained within a 3.0-
kilobase-pair EcoRI-HindIII fragment (35). The libraries
were screened with a RAS2 probe. Positive candidates
pSTS13, pSTS35, and pSTS37 were isolated from their
respective libraries.
Biological activity of the cloned genes was assayed in the
following manner. The 3.0-kilobase-pair EcoRI-HindIII frag-
ments were cloned into the URA3 integration vector YIp5
(2), and the resultant plasmids were digested with ClaI,
which cleaves within the RAS2 locus (35). The linearized
plasmids were used to transform strain SP1, and the Ura+
transformants were tested for growth at 37°C. A YIp5-based
plasmid containing wild-type RAS2 served as a negative
control.
Localization of the RAS2(Ts) activity. PstI cleaves the
RAS2 coding sequence within codons 65 and 66 (35). Chi-
meric plasmids encoding the first 65 amino acids from the
RAS2(Ts) alleles and the remaining 257 amino acids from
RAS2VaI-19 were constructed by transfer of the appropriate
EcoRI-PstI fragments of the pSTS plasmids into vector arms
provided by pRAS2Val-l9. Likewise, chimeric plasmids en-
coding the C-terminal 257 amino acids of the RAS2(Ts)
alleles and the first 65 amino acids of RAS2Va1-19 were
constructed by transfer of the appropriate PstI-HindIII
fragments of the pSTS plasmids into vector arms provided
by pRAS2Val-l9. Biological activity was assayed as described
above.
Oligonucleotide-directed mutagenesis. The EcoRI-PstI
fragments of pRAS2 and pRAS2Val-19 (26) were transferred
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into M13 vectors. Single-stranded DNA was annealed to
oligonucleotides, extended, and transformed into ung Esch-
erichia coli as described before (27, 45). The candidate
mutants were then sequenced. Plasmids pRAS2AIU22,
pRAS2 25, pRAS2ValI19 Ala-22, and pRAS2Val-l9, Pro-25
were constructed by transfer of the EcoRI-PstI fragments
from the mutant pUC plasmids into vector arms provided by
pRAS2. Biological activity was assayed as described above.
The oligonucleotide-derived mutants of H-ras were con-
structed in pUC vectors with SaIl-BamHI fragments con-
taining either H-rasval12 or wild-type H-ras, as described in
reference 25. The mutant H-ras alleles were transferred into
the GALIO expression vector YEP51 (4) as described previ-
ously (25). The HIS3+ integration vectors pGAL1O-H-
rasAla-15 and pGALJ-H-rasVal-12, Ala-15 were constructed by
transferring the EcoRI-XbaI fragments containing the mu-
tant GALJO-H-ras alleles into a pBR322-based vector con-
taining HIS3.
Other plasmids. YEpRAS2-1, YEpRAS2VUIl9, YEpCDC
25-1, and YEpTPKI are YEp13-based plasmids that have
been described previously (6, 35, 43). pRG2 contains the
3.0-kilobase-pair EcoRI-HindIII fragment from pRAS2 in-
serted into the intermediate copy number vector pHV1 (J.
Nikawa, unpublished data). pHV1 contains the polylinker
from pUC18, the HIS3 gene, and an HpaI-HindIII fragment
from 2,um including the origin of replication but lacking
REP3 (5).
RESULTS
Isolation and characterization of temperature-sensitive
RAS2 alleles. We have isolated several phenotypic revertants
of the rasi - RAS2Va-19 strain PT1-6, using heat shock
survival after stationary phase as a selective assay (36). As
reported previously, 43 heat-shock-resistant revertants have
been isolated at 25°C that have the additional property of
temperature-sensitive growth at 35°C (36). Eighteen of these
43 temperature-sensitive revertants appeared to be intra-
genic revertants for the following reason: when mated to
cells with the RAS2VaIl9 mutant allele, heat-shock-sensitive
diploid cells were formed and when mated to wild-type cells,
heat-shock-resistant diploid cells were formed. These results
are consistent with the occurrence of suppressor lesions
within the RAS2Val-l9 gene carried by PT1-6.
Three of these 18 revertants (STS1, STS3, and STS8) were
mated to wild-type cells, and the resultant diploids were
sporulated and dissected. Tetrad analysis confirmed the
intragenic nature of the phenotypic reversion (4:0 segrega-
tion of heat shock resistance to heat shock sensitivity in 35
complete tetrads). This analysis also indicated that the
temperature-sensitive alleles segregated independently of
RAS] but required the absence of RASJ (rasl::URA3) for
phenotypic penetrance (31 of 70 rasl- haploids were tem-
perature sensitive, and 0 of 70 RASI+ haploids were tem-
perature sensitive). Thus, these three strains appeared to
contain recessive, temperature-sensitive ras2 alleles
[ras2(Ts)]. Complementation tests with a mating strain con-
structed from one of these crosses showed that 15 of 18 of
these revertants behaved as if they also contained recessive
ras2(Ts) alleles. However, 3 of the 18 revertants behaved as
if they contained dominant RAS2(Ts) alleles since they
formed temperature-sensitive diploids when mated to strains
containing wild-type RAS genes.
To confirm that these three particular revertants (STS13,
STS35, and STS37) contained dominant temperature-sensi-
tive RAS2 alleles, two of them (SDS13 and STS37) were
TABLE 1. Ability of overexpressed genes to suppress the
temperature-sensitive defect of mutant RAS2 strains
Suppression of temperature-sensitive phenotype by
Strain' high-copy plasmidsb
RASI RAS2 RAS2vals CYR] TPKI
STS1 + + + + +
STS3 + + + + +
STS8 + + + + +
STS13 - - + + +
STS35 - - + + +
STS37 + + + + +
a All STS strains were derived from PT1-6 (rasl- RAS2val-19) and con-
tained temperature-sensitive ras2 or RAS2 alleles as described in the text.
b STS strains were transformed with YEp13-based vectors containing
RASI, RAS2, RAS2va-l9, CYRI, or TPKI (see Materials and Methods). Five
transformants from each group were patched onto SC-Leu plates and replica
plated onto YPD plates for assessing growth at 35°C. YEp13 transformants
served as a negative control.
mated to a wild-type strain and the resultant diploids were
subjected to tetrad analysis. In 10 complete tetrads from
each cross, the temperature-sensitive phenotype segregated
2:2 despite the presence of wild-type RAS]. A RASI +
temperature-sensitive strain from the STS13 cross (RS60-
12D) was mated to the ras2::URA3 strain KP-2 to study
linkage of the temperature-sensitive phenotype to the RAS2
locus. The segregation pattern of Ura+ and Ts- indicated
complete linkage of the temperature-sensitive phenotype to
the RAS2 locus (no recombinants in 23 complete tetrads).
We therefore concluded that STS13 contains a dominant
temperature-sensitive RAS2 allele [RAS2(Ts)]. Proof that
the other two strains (STS35 and STS37) contain dominant
RAS2tS alleles comes from cloning experiments described in
a later section. Thus, there are two classes of intragenic
mutations of RAS2Val19 that revert the RAS2Val-l9 pheno-
type and have temperature-sensitive function: the predomi-
nant class (15 of 18), composed of typical recessive loss-
of-function temperature-sensitive alleles; and the other class
(3 of 18), composed of dominant RAS2(Ts) alleles.
To explore the nature of the dominant interference with
growth, the three revertants containing dominant RAS2(Ts)
alleles were transformed with various high-copy plasmids
which overexpress genes of the RAS/cyclic AMP pathway.
As a control, three strains containing recessive ras2(Ts)
alleles (and rasl:: URA3) were transformed with the same
plasmids. Growth at 35°C was restored in all six of these
mutant strains by overexpression of the adenylate cyclase
gene CYR] (24) or by overexpression of the cyclic AMP-
dependent protein kinase gene TPKI (43; see Table 1). Thus,
downstream activation of the cyclic AMP pathway can
overcome the temperature-sensitive block in cell growth
imposed by both recessive rasl- ras2(Ts) mutations and the
dominant RAS2(Ts) mutations. As expected, overexpression
of RASI or RAS2 restored growth at 35°C to the rasi -
ras2(Ts) mutant (Table 1). The temperature-sensitive defect
of two of the dominant RAS2(Ts) mutants, however, was not
overcome by overexpression of wild-type RAS] or RAS2,
although the temperature-sensitive defect of STS37 was
suppressed (Table 1). Even vast overexpression of wild-type
RAS2, using the GALIO promoter, cannot reverse the tem-
perature-sensitive defect of dominant RAS2(Ts) mutants
STS13 and STS35 (data not shown). Some of the dominant
RAS2(Ts) alleles are therefore capable of blocking RAS
function even in the presence of a vast excess of wild-type
RAS. Thus, it is unlikely that these dominant RAS2(Ts)
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392 POWERS ET AL.
proteins are interfering with wild-type RAS proteins by
forming ineffective multimeric RAS protein complexes, a
common mechanism of inhibition found in dominant-inter-
fering mutants (22). The effect of the RAS2(Ts) protein from
STS37, however, is competitively reversed by overexpres-
sion of wild-type RAS.
Overexpression of RAS2Vall9 does overcome the temper-
ature-sensitive block induced by all of the RAS2(Ts) alleles
(Table 1). Furthermore, the heat-shock-sensitive phenotype
induced by RAS2Val-l9 is not influenced by the presence of
RAS2(Ts) alleles (data not shown). Thus, the dominant
RAS2(Ts) alleles, although they are capable of blocking the
function of wild-type RAS and, in some cases, overex-
pressed wild-type RAS, do not interfere with the function of
activated RAS2Va-119. In fact, even single-copy RAS2Val-l9 is
epistatic to all of the dominant RAS2(Ts) alleles, since
diploids formed between RAS2(Ts) strains and RAS2Val-l9
strains are fully heat shock sensitive and are not temperature
sensitive for growth. It seems likely, therefore, that the
dominant RAS2(Ts) proteins are blocking a step required for
the activation of wild-type yeast RAS proteins and that they
are not blocking a step involved in the interaction of RAS
proteins with their target effector.
Molecular analysis of the dominant temperature-sensitive
RAS2 alleles. We cloned the RAS2(Ts) alleles from STS13,
STS35, and STS37 by screening genomic libraries with a
RAS2 probe (see Materials and Methods). The cloned
RAS2(Ts) alleles were transferred to the yeast integration
vector YIp5 and transformed into yeast strain SP1 (see
Materials and Methods). All three cloned RAS2(Ts) alleles
were capable of dominantly inducing temperature-sensitive
growth at 37°C (data not shown).
To localize the RAS2 mutations that altered their proper-
ties, we made chimeras between the dominant RAS2(Ts) and
wild-type RAS2 genes (see Materials and Methods). The
temperature-sensitive lesions for all three alleles were local-
ized to within DNA encoding the first 66 N-terminal amino
acids. We sequenced the three cloned genes within this
region, and in each case a single nucleotide change, resulting
in a single amino acid substitution, was detected. In STS13
and STS35, a G-to-C transversion in the 22nd codon (GGT to
GCT) resulted in a substitution of alanine for glycine. In
STS37, a G-to-C transversion in the 25th codon (GCT to
CCT) resulted in a substitution of proline for alanine. To
confirm that these single amino acid substitutions caused the
dominant temperature-sensitive phenotype, and to test
whether these substitutions would cause a dominant
temperature-sensitive phenotype if position 19 encoded
glycine (wild type) instead of valine, we constructed four
RAS2 genes by oligonucleotide-directed mutagenesis:
RAS2Val-19, Ala-22 RAS2Val-l9, Pro-25, RAn2AIa-22, and
RAS2Pro-25 (see Materials and Methods). All four of these
genes were transferred into the yeast integration vector YIp5
and transformed into strain SP1, and all four genes induced
temperature-sensitive growth (data not shown). We con-
clude, therefore, that the amino acid substitution observed in
the RAS2(Ts) alleles of STS13 and STS35 (a glycine-to-
alanine substitution at position 22) and the amino acid
substitution observed in the RAS2(Ts) allele of STS37 (an
alanine-to-proline substitution at position 25) are each suffi-
cient to convert a wild-type RAS2 into a dominantly inter-
fering gene.
Ability of CDC25 overexpression to reverse the effect of the
dominant-interfering RAS2(Ts) genes. The ability of the dom-
inant RAS2Val-19, Ala-22 alleles to block cell growth even in
the presence of excess wild-type RAS, but not when
TABLE 2. Evidence that suppression of the temperature-
sensitive phenotype of STS13 requires both overexpression of
CDC25 and the presence of RAS2'
Presence of gene on No. of colonies with
high-copy plasmids given phenotype
RAS2 CDC25 Ts' Ts-
-- 2 145
+ 0 54
+ - 1 343
+ + 349 11
a Strain STS13 (rasl- RAS2Val-19 Ala-22) was transformed with both an
episomal RAS2 plasmid (HIS3+) and a high-copy CDC25 plasmid (LEU2+).
After plasmid segregation (see text), the temperature-sensitive phenotype of
individual colonies was scored at 35°C on YPD plates, as was the presence or
absence of the two plasmids.
RAS2va-19 is present, is reminiscent of the growth inhibition
induced by disruption of CDC25 (6, 38). We wished there-
fore to explore the possibility that the dominant RAS2(Ts)
genes might block the activation of wild-type RAS proteins
by depleting CDC25 protein. The rasi - RAS2(Ts) mutants
STS13 and STS37, and their RAS] + counterparts RS60-3A
and RS68-2B (see Materials and Methods), were trans-
formed with the high-copy vector YEpCDC25-J (6). We
found that like rasl- ras2(Ts) strains, the rasl- RAS2(Ts)
strains did not have their temperature-sensitive defect re-
versed by overexpression of CDC25. However, the temper-
ature-sensitive defect of the RAS]+ RAS2(Ts) strains was
overcome by overexpression of CDC25 (data not shown). It
would appear, then, that CDC25 overexpression can reverse
the temperature-sensitive defect induced by RAS2(Ts) alle-
les, but only in the presence of wild-type RAS.
To confirm this finding, the rasl- RAS2Val-l9, Ala-22 strain
STS13 was transformed sequentially with YEpCDC25-1 and
then with the episomal RAS2 vector pRG2 (see Materials
and Methods). Double transformants were allowed to grow
in nonselective media overnight to allow for loss of either or
both of the CDC25 and RAS2 plasmids. Individual cells were
allowed to grow into colonies and then replica plated to
assess the segregation of three phenotypes: temperature-
sensitive growth, the presence of high-copy CDC25 (Leu+),
and the presence of wild-type RAS2 (His'). The results
shown in Table 2 demonstrate the requirement of both
overexpression of CDC25 and the presence of wild-type
RAS2 to overcome the temperature-sensitive block induced
by RAS2Vall9. Ala-22. Thus, we confirmed that overexpres-
sion of CDC25 reverses the temperature-sensitive defect
imposed by RAS2val-l9, Ala-22 only in the presence of wild-
type RAS protein. This result suggests to us that the
RAS2Val-22, Ala-22 proteins can deplete the cell of normal,
endogenous levels of CDC25 activity.
Analogous properties of H-rasva"l2, Ala-15 and H-rasAa-ls
mutants. Wild-type mammalian H-ras can suppress the
growth defects induced by disruption of CDC25 (31),
whereas high expression of yeast RAS proteins does not (6,
31). This has raised the possibility that H-ras protein does
not interact with CDC25 protein. We decided to reexamine
this question by constructing H-ras mutants with amino acid
substitutions analogous to the substitutions found in the
dominant interfering RAS2(Ts) mutant genes. We used oli-
gonucleotide site-directed mutagenesis to construct two H-
ras genes: H-rasA,a-l5 and H-rasval-12, Ala-15 (see Materials
and Methods). These genes were transferred into the galac-
tose-inducible yeast expression vector YEp51 (5). We
transformed the wild-type strain SP1 with YEp51 vectors
MOL. CELL. BIOL.
 o
n
 April 5, 2012 by M
AIN LIBRARY
http://m
cb.asm
.org/
D
ow
nloaded from
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TABLE 3. Ability of overexpressed genes to override growth
inhibition of H-rasVal-12, Ala-15a
Growth of colonies (no.) on
Overexpressed gene YP + galactose
Ts- Ts'
None 113 0
RAS2 55 2
TPKI 1 87
CDC25 2 120
a Strain SDR3, which expresses H-rasVall2 Ala-65 when induced with
galactose (see text), was transformed with various high-copy plasmids,
including YEp13, YEpRAS2, YEpTPKI, and YEpCDC25-1 (see Materials
and Methods). Four days later, the transformed colonies were replica plated
onto either glucose- or galactose-containing plates and incubated at 37°C. The
ability of the high-copy plasmids to restore growth at 37°C on galactose-
containing plates was scored after 2 days.
expressing wild-type H-ras, H-rasval2, H rasAlal5, and H-
rasval2, Ala-l5 and tested the effect of galactose-induced
expression on the temperature-sensitive growth properties
of the transformants. The expression of neither wild-type
H-ras nor H-rasval12 interfered with growth on galactose-
containing medium at any temperature tested. However,
expression of both H-rasAla-l5 and H-rasvall9, Ala-15 blocked
growth on galactose at all temperatures tested. The effect
was more pronounced at higher temperatures (total growth
inhibition at 35°C) and somewhat leaky at 23°C (thin patches
formed after 4 days).
We tested whether various high-copy plasmid vectors
containing genes of the RAS/cAMP pathway could reverse
the effects of the mutant H-ras genes. Since the YEp51
vectors and our CDC25 overexpression vectors both utilize
the LEU2 marker, we constructed HIS3+ vectors containing
H-rasAa'l5 and H_raSVal-19, Ala-l (see Materials and Meth-
ods). These integration vectors were transformed into SP1
after cleavage within the HIS3 gene by XhoI to site direct
integration into the HIS3 locus. Both of these integration
vectors were found to block growth in the presence of
galactose, although the effect was much more temperature
dependent than with the high-copy episomal vectors ex-
pressing the mutant H-ras genes. Strain SDR-3, which
expresses H-raSVal-l2 Ala-15 when induced with galactose,
was transformed with high-copy vectors which overex-
pressed wild-type RAS2, the cAMP-dependent protein ki-
nase gene TPKJ, and CDC25. The effect of these high-copy
plasmids is shown in Table 3. As expected, overexpression
of TPKI reversed the temperature-sensitive defect. Overex-
pression of wild-type RAS2 did not enhance cell growth
(Table 3), indicating that the block of wild-type RAS function
cannot be inhibited by an abundance of wild-type RAS
protein. Overexpression of CDC25 completely reverses
the temperature-sensitive defect (Table 3). Thus, the H-
rasVal-12. Ala-15 mutant, like the dominant RAS2(Ts) alleles,
acts to block RAS function by depleting the normal endog-
enous supply of CDC25 activity. This result suggests that
H-ras protein can interact with CDC25 protein in a manner
analogous to the interaction of RAS2 protein with CDC25
protein.
DISCUSSION
We have described dominant mutations of RAS2 and
H-ras which interfere with wild-type RAS function in S.
cerevisiae. The evidence is clear that the mutant RAS genes
interfere with the activation of normal RAS proteins, since
the interference can be overcome by expression of mutation-
ally activated RAS2Va L9. More specifically, interfering RAS
mutants appear to block CDC25 activity, since overexpres-
sion of CDC25 protein, which acts upstream of RAS protein
and is required for its activation (6, 38), can overcome the
interference if wild-type RAS protein is also present. Over-
expression of CDC25 has no apparent phenotype in an
otherwise wild-type cell (6), nor does it suppress the tem-
perature-sensitive defect of yeast cells expressing only tem-
perature-sensitive RAS proteins. We therefore propose that
interfering RAS protein forms a complex with CDC25 pro-
tein and thereby blocks its activity.
We propose that the mechanism of interaction between
CDC25 and RAS proteins may be evolutionarily conserved,
since expression of H-rasAla-15 seems to deplete the normal
supply of CDC25 protein in S. cerevisiae. Moreover, Sigal
and co-workers have reported that an H-rasAsn-l6 mutation
also induces a dominant temperature-sensitive growth arrest
that likewise can be reversed by the expression of an
activated RAS2 mutant gene (40). Recently, Feig and Cooper
reported similar mutations in mammalian cells (14). They
found that an H-ras sn-17 mutant inhibits proliferation of
mouse NIH 3T3 cells and that the effect of H-rasAsnl7 is
reversed by expression of the activated mutant H-rasv"'l12
gene (14). This strongly suggests to us that a protein with the
properties of the CDC25 protein also exists in mammalian
cells and is required for activation of wild type H-ras protein.
We have not tested the H-rasAsn-l7 mutant in yeast cells or
the H-rasA a-15 mutant in mammalian cells.
The amino acid substitutions occurring in the dominant
RAS2's proteins are located in a highly conserved guanine-
nucleotide-binding region (Table 4). The mutation found by
Feig and Cooper is located in this region (14), as is the
mutant H-ras described by Sigal and co-workers (40). The
RAS-like gene products, such as RHO, YPT, and SEC4, and
G proteins, such as G^a, Gia, and transducins, have con-
served residues corresponding to residues 10 to 18 of the
human H-ras protein and virtual identity at positions which
correspond to residues 15, 16, and 17 (18, 21, 23, 28-30, 34,
39, 42). This region corresponds to a consensus nucleotide-
TABLE 4. Partial amino acid sequence of RAS and RAS-like proteins in region of interfering mutant proteinsa
Protein Sequence Positions Reference(s)
I I I I
H-ras GLY ALA GLY GLY VAL GLY LYS SER ALA 10-18 13
RAS1,2 GLY GLY GLY GLY VAL GLY LYS SER ALA 17-25 35
YPT1 GLY ASN SER GLY VAL GLY LYS SER CYS 15-23 18, 21
SEC4 GLY ASP SER GLY VAL GLY LYS SER CYS 27-35 39
Transducin GLY ALA GLY GLY SER GLY LYS SER THR 40-48 28, 34
a The region of H-ras and other related proteins where the mutations of the dominant-interfering genes are localized includes a highly conserved GXXXXGK
sequence (in boldface) found in virtually all guanine-nucleotide-binding proteins (12). Arrows indicate positions where amino acid substitutions within H-ras or
RAS2 proteins lead to proteins with interfering properties.
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[RAS. GDP] CDC25
GDP
GTP
[RAS.GTP CDC25]
[RAS*GTP] CDC25
FIG. 1. Model for RAS and CDC25 protein interactions. In step
1, RAS complexed to GDP binds to CDC25 protein. In step 2,
CDC25 stabilizes the nucleotide-free state of RAS, and GDP disso-
ciates. In step 3, GTP binds to RAS. This terminates the interaction,
and in step 4 CDC25 protein is free to interact with another RAS
protein. According to this model, the dominant interfering RAS
proteins cannot proceed through steps 3 and 4 and instead remain
bound to CDC25, preventing it from interacting with wild-type RAS
protein.
binding sequence, GXXXXGK (Table 4). The interfering
mutant H-ras proteins of Feig and Cooper and of Sigal and
co-workers both exhibit altered affinity for guanine nucleo-
tides (14, 40). This suggests that alterations in guanine-
nucleotide-binding properties underlie the ability of the
mutant RAS proteins to deplete CDC25 activity in cells.
The results presented in this report lead us to propose a
simple model for the inhibition of wild-type RAS function by
the dominant RAS2(Ts) mutants (Fig. 1). We propose that
RAS and CDC25 proteins normally undergo a transient,
direct interaction, similar to the transient interaction of
receptors with G proteins (20, 41). In this model, CDC25
proteins interact with the GDP-bound form of RAS proteins
and, by virtue of stabilizing the transitional state of nucle-
otide-free RAS protein, catalyze nucleotide exchange. This
mechanism of catalysis (stabilization of the nucleotide-free
transitional state) has been proposed by Stryer for the
activation of transducin by photorhodopsin (41). When GTP
binds to RAS protein, the interaction is terminated and
CDC25 protein is free to interact with another RAS protein.
We propose that the dominant-interfering RAS proteins
remain bound to CDC25 protein, because either a severely
impaired ability to bind guanine nucleotides or a selective
inability to bind GTP results in a failure to terminate the
interaction with CDC25 protein. The net result of the inter-
action between CDC25 and interfering RAS proteins is to
prevent CDC25 protein from interacting with wild-type RAS
proteins. This causes a cdc25-like state, consistent with the
genetic experiments we described.
We envision that mutants in other RAS-like genes, similar
to the dominant-interfering mutants we have described, may
aid in identification of their respective CDC25-like gene
product. The ability of overexpression of CDC25 to suppress
the dominant RAS2(Ts) mutations only in the presence of
wild-type RAS forms the basis for a highly selective genetic
screen. We also envision that mutant RAS genes encoding
proteins blocked in other steps of the RAS protein cycle can
be identified and utilized for the study of other proteins with
which RAS proteins interact. In support of this, an H-ras
mutant capable of interfering with the function of RAS2Va-l9
has been isolated and characterized recently (T. Michaeli, et
al., unpublished data). The existence of interfering mutants
in signal transduction pathways may be quite general (22).
For example, we have found dominant-interfering forms of
adenylate cyclase in yeast cells which appear to block RAS
function (J. Field et al., unpublished data). Analogous mu-
tants may exist for the targets of H-ras proteins in mamma-
lian cells. We have seen that mutant oncogene products may
interfere with cell growth. As a further generalization, we
may be able to generate interfering mutants of "recessive"
oncogenes, such as the retinoblastoma gene (9, 17), which
thereby become dominant oncogenes.
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